Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HSCT for Neuro-Epithelial and Solid Tumors
NCT02653196Phase 1Terminated
- Sponsor
- Montefiore Medical Center
- Start
- Sep 2015
- Primary completion
- Aug 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic hematopoietic stem cells in neuroepithelial tumor and solid tumor, sponsored by Montefiore Medical Center. Primary endpoint: Progression-Free Survival at 6 months. Started Sep 2015; status: terminated.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
neuroepithelial tumorsolid tumor
Beyond the preview
Go deeper on NCT02653196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653196.